Background/Aim: Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional signaling protein implicated in carbohydrate metabolism, inflammation, cancer growth and progression, anoikis resistance, angiogenesis, and metastasis. However, signaling pathways of ANGPTL4 in cholangiocarcinoma (CCA) remain unknown. The aim of this study was to explore ANGPTL4-related signaling proteins and pathways associated with CCA biology. Materials and Methods: ANGPTL4 of CCA cells was silenced by small interfering RNA (siRNA) with scramble control and ANGPTL4-related signaling proteins were investigated using mass spectrometry, bioinformatics tools and molecular docking. Results: Among the 321 differentially expressed proteins, 151 were downregulated. Among them, bioinformatic analyses revealed that ANGPTL4 interacts with DNA-dependent protein kinase catalytic subunit (PRKDC) and 60S ribosomal protein L21 (RPL21) via AKT serine/threonine kinase 1 (AKT1), mechanistic target of rapamycin kinase (MTOR) and ribosomal protein L5 (RPL5). Online database analysis showed that mRNA and protein expression levels of ANGPTL4-related signaling proteins were significantly higher in CCA than in normal tissues. Moreover, a high mRNA expression level was associated with high tumor grade (p<0.0001) and lymph node metastasis (p<0.0001). Conclusion: The signaling pathway of ANGPTL4 in CCA progression might be regulated by PRKDC and RPL21. Furthermore, high expression of ANGPTL4-related signaling proteins has potential to be used in clinical prognosis.Cholangiocarcinoma (CCA) is a type of highly aggressive cancer that can develop anywhere in the biliary tree or within the liver parenchyma (1). It is a rare cancer worldwide, but it is highly prevalent in Thailand, with the highest prevalence of 85/100,000 population being recorded in northeast Thailand and in association with the high prevalence of infection with the oncogenic liver fluke (Opisthorchis viverrini) (2-4). Although complete surgical resection is the only curative treatment for CCA, the postoperative 5-year survival rate of patients remains low (11.2%) due to late presentation of clinical symptoms (5, 6). Carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are currently used tumor markers for clinical diagnosis/prognosis of CCA. However, elevation of these markers has also been found in benign biliary diseases, pancreatic cancer, and colorectal cancer, amongst others (7-9). Hence, developing reliable biomarkers and exploring the mechanisms underlying CCA progression are essential to improve the outcomes of patients with CCA.Angiopoietin-like protein 4 (ANGPTL4) is a secreted protein with a highly hydrophobic signal peptide and has an N-terminal coiled-coil domain and a C-terminal fibrinogen-like fragment (10). It has a variety of biological roles in both normal and 490